DPP-4抑制剂-话题@MedSci

#DPP-4抑制剂#

44篇内容 | 2457人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2178005, encodeId=03b521e8005d3, content=<a href='/topic/show?id=31618386e18' target=_blank style='color:#2F92EE;'>#胰岛素#</a> <a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a> <a href='/topic/show?id=9d5d44888a9' target=_blank style='color:#2F92EE;'>#妊娠期糖尿病#</a> <a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=JAMA Intern Med：GLP-1受体激动剂和其他二线降糖药在妊娠早期的安全性, objectType=article, longId=807481, objectId=89b680e48114, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231229/1703830837087_5490734.jpg, objectUrl=/article/show_article.do?id=89b680e48114, replyNumber=0, likeNumber=122, createdTime=2023-12-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=89b680e48114, moduleTitle=JAMA Intern Med：GLP-1受体激动剂和其他二线降糖药在妊娠早期的安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89b680e48114)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1374137, encodeId=ee1213e41371b, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=【每日播报】-磺脲类药物联合DPP-4抑制剂的疗效, objectType=article, longId=738851, objectId=9b3ae388512b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b3ae388512b, replyNumber=0, likeNumber=74, createdTime=2022-09-11, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b3ae388512b, moduleTitle=【每日播报】-磺脲类药物联合DPP-4抑制剂的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b3ae388512b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374136, encodeId=55bc13e413627, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较, objectType=article, longId=736572, objectId=7caae365721d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7caae365721d, replyNumber=0, likeNumber=71, createdTime=2022-08-24, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7caae365721d, moduleTitle=SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7caae365721d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374135, encodeId=7b3213e4135c9, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险, objectType=article, longId=735642, objectId=ed39e3564211, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed39e3564211, replyNumber=0, likeNumber=97, createdTime=2022-08-13, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed39e3564211, moduleTitle=Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed39e3564211)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374134, encodeId=a5f213e41346c, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, objectType=article, longId=723796, objectId=c62be2379617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62be2379617, replyNumber=0, likeNumber=82, createdTime=2022-04-09, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62be2379617, moduleTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62be2379617)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374133, encodeId=4bf413e413392, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响, objectType=article, longId=301367, objectId=c4b830136e91, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4b830136e91, replyNumber=0, likeNumber=68, createdTime=2022-03-23, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4b830136e91, moduleTitle=Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4b830136e91)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374132, encodeId=314013e41326e, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, objectType=article, longId=300317, objectId=525d30031e63, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525d30031e63, replyNumber=0, likeNumber=152, createdTime=2022-03-10, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525d30031e63, moduleTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525d30031e63)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374131, encodeId=477413e4131c9, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关, objectType=article, longId=218302, objectId=3ada21830258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ada21830258, replyNumber=0, likeNumber=94, createdTime=2021-10-11, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ada21830258, moduleTitle=Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ada21830258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374130, encodeId=004213e4130fe, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=BMJ子刊：基于真实世界研究，长期使用DPP-4抑制剂对2型糖尿病患者的安全性和有效性, objectType=article, longId=205874, objectId=7eb72058e492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7eb72058e492, replyNumber=0, likeNumber=92, createdTime=2021-01-20, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7eb72058e492, moduleTitle=BMJ子刊：基于真实世界研究，长期使用DPP-4抑制剂对2型糖尿病患者的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7eb72058e492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374129, encodeId=16d313e41299a, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=Diabetes Obes Metab：2型糖尿病患者服用DPP-4抑制剂与肺炎风险的关系, objectType=article, longId=198041, objectId=482f198041a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=482f198041a4, replyNumber=0, likeNumber=82, createdTime=2020-07-27, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=482f198041a4, moduleTitle=Diabetes Obes Metab：2型糖尿病患者服用DPP-4抑制剂与肺炎风险的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=482f198041a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374128, encodeId=a60513e412842, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=Metabolism：DPP-4抑制剂在2型糖尿病治疗中的疗效和安全性, objectType=article, longId=196067, objectId=8fa119606e77, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa119606e77, replyNumber=0, likeNumber=109, createdTime=2020-06-19, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa119606e77, moduleTitle=Metabolism：DPP-4抑制剂在2型糖尿病治疗中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fa119606e77)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374127, encodeId=da9413e4127bd, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=Diabetes Obes Metab：2型糖尿病患者DPP-4抑制剂治疗与COVID-19, objectType=article, longId=194932, objectId=a64319493248, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a64319493248, replyNumber=0, likeNumber=97, createdTime=2020-05-30, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a64319493248, moduleTitle=Diabetes Obes Metab：2型糖尿病患者DPP-4抑制剂治疗与COVID-19, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a64319493248)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374126, encodeId=9ebc13e4126ad, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=DPP-4抑制剂临床应用专家指导建议解读 | CDS2019, objectType=article, longId=183694, objectId=83b71836947d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83b71836947d, replyNumber=0, likeNumber=107, createdTime=2019-11-29, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83b71836947d, moduleTitle=DPP-4抑制剂临床应用专家指导建议解读 | CDS2019, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83b71836947d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374125, encodeId=84cc13e4125e5, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=客官厉害了！国产原创DPP-4抑制剂盛格列汀“免二进三”, objectType=article, longId=183020, objectId=e12c1830202d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12c1830202d, replyNumber=0, likeNumber=106, createdTime=2019-11-16, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12c1830202d, moduleTitle=客官厉害了！国产原创DPP-4抑制剂盛格列汀“免二进三”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e12c1830202d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374124, encodeId=48d813e41248c, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=DPP-4抑制剂——心血管疾病史患者的二联用药优选, objectType=article, longId=177142, objectId=867b1e714287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=867b1e714287, replyNumber=0, likeNumber=79, createdTime=2019-08-09, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=867b1e714287, moduleTitle=DPP-4抑制剂——心血管疾病史患者的二联用药优选, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=867b1e714287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374123, encodeId=082e13e412342, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=DPP-4抑制剂——二联用药中的换药优选, objectType=article, longId=176240, objectId=7a4b1e6240bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a4b1e6240bd, replyNumber=0, likeNumber=107, createdTime=2019-07-28, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a4b1e6240bd, moduleTitle=DPP-4抑制剂——二联用药中的换药优选, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a4b1e6240bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374122, encodeId=fc0213e412236, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=为什么DPP-4抑制剂是二甲双胍加药的优选？, objectType=article, longId=176161, objectId=26211e6161fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26211e6161fd, replyNumber=0, likeNumber=80, createdTime=2019-07-27, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26211e6161fd, moduleTitle=为什么DPP-4抑制剂是二甲双胍加药的优选？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26211e6161fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374121, encodeId=c3a413e412151, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=DPP-4抑制剂，二甲双胍加药优选, objectType=article, longId=176117, objectId=73031e611783, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73031e611783, replyNumber=0, likeNumber=96, createdTime=2019-07-26, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73031e611783, moduleTitle=DPP-4抑制剂，二甲双胍加药优选, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73031e611783)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374120, encodeId=62df13e4120b7, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=AP&T： DPP-4抑制剂维达列汀可抑制胃调节并增加胰高血糖素样肽-1血浆水平, objectType=article, longId=162307, objectId=fc3b16230e8f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc3b16230e8f, replyNumber=0, likeNumber=103, createdTime=2019-03-15, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc3b16230e8f, moduleTitle=AP&T： DPP-4抑制剂维达列汀可抑制胃调节并增加胰高血糖素样肽-1血浆水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc3b16230e8f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374119, encodeId=730a13e411914, content=<a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a>, objectTitle=DPP-4抑制剂临床应用专家共识, objectType=article, longId=157552, objectId=86a515e552ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86a515e552ea, replyNumber=0, likeNumber=79, createdTime=2019-01-09, rootId=0, userName=ewsr1, userId=a8d7373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86a515e552ea, moduleTitle=DPP-4抑制剂临床应用专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86a515e552ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

DPP-4抑制剂

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#胰岛素# #DPP-4抑制剂# #妊娠期糖尿病# #GLP-1受体激动剂#

JAMA Intern Med：GLP-1受体激动剂和其他二线降糖药在妊娠早期的安全性

2023-12-29发表于上海

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

【每日播报】-磺脲类药物联合DPP-4抑制剂的疗效

2022-09-11

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较

2022-08-24

zhaojie88 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

Cardiovasc Diabetol：使用SGLT2i、GLP1RA和DPP-4抑制剂治疗的2型糖尿病患者发生房颤的风险

2022-08-13

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响

2022-04-09

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响

2022-03-23

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系

2022-03-10

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关

2021-10-11

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

BMJ子刊：基于真实世界研究，长期使用DPP-4抑制剂对2型糖尿病患者的安全性和有效性

2021-01-20

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

Diabetes Obes Metab：2型糖尿病患者服用DPP-4抑制剂与肺炎风险的关系

2020-07-27

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

Metabolism：DPP-4抑制剂在2型糖尿病治疗中的疗效和安全性

2020-06-19

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

Diabetes Obes Metab：2型糖尿病患者DPP-4抑制剂治疗与COVID-19

2020-05-30

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

DPP-4抑制剂临床应用专家指导建议解读 | CDS2019

2019-11-29

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

客官厉害了！国产原创DPP-4抑制剂盛格列汀“免二进三”

2019-11-16

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

DPP-4抑制剂——心血管疾病史患者的二联用药优选

2019-08-09

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

DPP-4抑制剂——二联用药中的换药优选

2019-07-28

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

为什么DPP-4抑制剂是二甲双胍加药的优选？

2019-07-27

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

DPP-4抑制剂，二甲双胍加药优选

2019-07-26

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

AP&T： DPP-4抑制剂维达列汀可抑制胃调节并增加胰高血糖素样肽-1血浆水平

2019-03-15

ewsr1 (审核中...)

前往app查看评论内容

#DPP-4抑制剂#

DPP-4抑制剂临床应用专家共识

2019-01-09

科室
- - 订阅+
  - 更多科室
工具
服务